Filtered By:
Cancer: Epithelial Cancer
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 20002 results found since Jan 2013.
Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment
CONCLUSIONS: In patients with newly diagnosed (advanced) or recurrent high-grade serous or endometrioid ovarian cancer, niraparib maintenance therapy improved progression-free survival compared with no maintenance therapy in tumours with HRD or HRP (GRADE: High). Because we identified no studies on the clinical utility of HRD testing, we cannot comment on how it would affect patient decisions and clinical outcomes.Over a 5-year time horizon, HRD testing for people with BRCA wild type could save $4,509 per person and lead to a loss of 0.116 QALY. The findings of our economic analyses are dependent on assumptions about the u...
Source: Ontario Health Technology Assessment Series - August 28, 2023 Category: General Medicine Authors: Ontario Health (Quality) Source Type: research
Protective effects of exogenous melatonin therapy against oxidative stress to male reproductive tissue caused by anti-cancer chemical and radiation therapy: a systematic review and meta-analysis of animal studies
ConclusionIn male rodents, melatonin therapy was related to improved testicular histopathology, reproductive hormones, testis and body weights, and reduced levels of oxidative markers in testicular tissues of male rodents. Future meticulous studies are recommended to provide a robust scientific backbone for human applications.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022355293, identifier CRD42022355293.
Source: Frontiers in Endocrinology - August 28, 2023 Category: Endocrinology Source Type: research
Investigation of the Host Kinome Response to Coronavirus Infection Reveals PI3K/mTOR Inhibitors as Betacoronavirus Antivirals
This study lays the groundwork for identifying broad-acting, host-targeted therapies to reduce betacoronavirus replication that can be rapidly repurposed during future outbreaks and epidemics. The proteomics, phosphoproteomics, and MIB-MS datasets generated in this study are available in the Proteomics Identification Database (PRIDE) repository under project identifiers PXD040897 and PXD040901.PMID:37634194 | DOI:10.1021/acs.jproteome.3c00182
Source: Cell Research - August 27, 2023 Category: Cytology Authors: Ethan J Fritch Angie L Mordant Thomas S K Gilbert Carrow I Wells Xuan Yang Natalie K Barker Emily A Madden Kenneth H Dinnon Yixuan J Hou Longping V Tse Izabella N Castillo Amy C Sims Nathaniel J Moorman Premkumar Lakshmanane Timothy M Willson Laura E Herr Source Type: research
